Management of benign prostate hyperplasia: An overview of α-adrenergic antagonist

Biological and Pharmaceutical Bulletin

Volumn 29, Issue 8, 2006, Pages 1554-1558

  Garg, Gopal ^a   Singh, Deependra ^a   Saraf, Swarnlata ^a   Saraf, Shailendra ^a  

^a PT RAVISHANKAR SHUKLA UNIVERSITY   (India)

Author keywords

adrenergic antagonist; Benign prostate hyperplasia; Prostate

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN; ANTIANDROGEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUNAZOSIN; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; DOXAZOSIN; FINASTERIDE; FOSFESTROL; GONADORELIN AGONIST; INDORAMIN; KETANSERIN; LABETOLOL; MOXISYLYTE; PHENOXYBENZAMINE; PRAZOSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; UNCLASSIFIED DRUG; URAPIDIL; YOHIMBINE;

BLADDER DISEASE; BLADDER NECK; BLADDER STONE; BLEEDING; CELL GROWTH; CHRONIC PROSTATITIS; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG HALF LIFE; DRUG INHIBITION; DRUG STRUCTURE; ERECTILE DYSFUNCTION; HEADACHE; HEMATURIA; HUMAN; HYPERTENSION; IMPAIRED BLADDER EMPTYING; INFECTION; KIDNEY FAILURE; KIDNEY FUNCTION; MICTURITION; NONHUMAN; ORTHOSTATIC HYPOTENSION; PROSTATE; PROSTATE HYPERTROPHY; RETROGRADE EJACULATION; REVIEW; SMOOTH MUSCLE TONE; TRANSURETHRAL ELECTROVAPORIZATION; TRANSURETHRAL RESECTION; URETHRA; URINARY TRACT INFECTION; URINARY TRACT OBSTRUCTION; URINE INCONTINENCE; URINE RETENTION; WELLBEING;

ADRENERGIC ALPHA-ANTAGONISTS; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PROSTATIC HYPERPLASIA;

EID: 33746664289     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.29.1554     Document Type: Review

References (57)

1. Chapple C. R., Smith D., J. Urol., 73, 117-123 (1994).
2. Ifterling J. P., Arch. Fam. Med., 1, 257-266 (1992).
3. Shapiro F., Lepop H., Urol. Clin. North Am., 22, 285-290 (1995).
4. Caire M., Plau A., Perlbert S., Br. J. Urol., 48, 255-263 (1976).
5. Haltgrewe H. L., Urology, 51, 1-7 (1998).
6. Khoury S., Cockett A., Prostate, 45, 194-199 (2000).
7. Clifford G. N., Logie J., Farmer R. D. T., Eur. Urol., 38, 48-53 (2000).
8. Jepsen J. V., Bruskewitz R. C., Urology, 51, 13-18 (1998).
9. Blaivas J. G., Urol. Clin. North Am., 23, 273-284 (1996).
10. Barry M. J., Cockett A. T. K., Haltgrewe H. L., J. Urol., 150, 351-358 (1993).
11. Ridgefield C. T., Boehringer Ingelheim Pharmaceutical Incorporated Flomay: 2000.
12. Rozsi X. C., Kortmann B. M., Sonke G. S., J. Urol., 165, 38-41 (2001).
13. Peters T. J., Donovan J. L., Kay H. E., J. Urol., 157, 885-889 (1997).
14. Andersson K. R., B.J.U. Int., 86, 23-30 (2000).
15. Tammela T., Drugs Aging, 10, 349-366 (1997).
16. Monda J. N., Oesterling J. F., Curr. Probl. Urol., 2, 100-142 (1992).
17. Lepor H., Rigaud G., J. Urol., 143, 533-537 (1990).
18. Mebust W. K., Haltgrewe H. L., J. Urol., 141, 243-247 (1989).
19. Wennberg J. E., Roos N., Sola L., Schori A., Jaffe R., JAMA, 257, 933-936 (1987).
20. Roos N. P., Wennberg J. E., Malenka D. J., N. Engl. J. Med., 320, 1120-1124 (1989).
21. Oesterling J. E., J. Androl., 12, 381-388 (1991).
22. Matzkin H., Chen J., Lewysohn O., Braf Z., J. Urol., 145, 309-312 (1991).
23. Weber J. P., Oesterling J. E., Peters C. A., Partin A. W., Chan D. W., Walsh P. C., J. Urol., 141, 987-992 (1989).
24. McConnell J. D., Urol. Clin. North Am., 17, 661-670 (1990).
25. Sufrin G., Coffey D. S., Invest. Urol., 13, 429-434 (1976).
26. McGinley J., Guerrero L., Gautier T., Peterson R. F., Science, 186, 1213-1215 (1974).
27. Staner E., J. Steroids Biochem. Mol. Biol., 37, 375-378 (1990).
28. Rittmaster R. S., N. Engl. J. Med., 330, 120-125 (1994).
29. Caine M., Perlberg S., Meretyk S., Br. J. Urol., 50, 551-554 (1978).
30. Hardman J. G., Limbird L. E., "Gilman & Goodman's The Pharmacological Basis of Therapeutics," 10th ed., ed. by Goodman L. S., Hardman J. G., Limbird L. E., McGraw-Hill, New York, 2001, pp. 243-245.
31. "The Merck Index," 12th ed., Merck Publishing, Whitehouse Station, 1996, p. 1077.
32. Fogler R., Shibata K., Horie K., Hirasawa A., Tsujimato G., Eur. J. Pharmacol., 288, 201-207 (1995).
33. O'Connell J., Chalmers D. H., Naylor A. M., Br. J. Pharmacol., 118, 871-878 (1996).
34. Cubeddu L. X., Am. Heart J., 116, 133-162 (1988).
35. Halmes B., Sorkin E. M., Drugs, 31, 467-499 (1986).
36. Hess H. J., Postgrad. Med., 5, 9-17 (1975).
37. Yang G., Tinnme T. L., Park S. H., Wu X., Wyllie M. G., Thompson T. C., Prostate, 33, 157-163 (1997).
38. Hedlund H., Anderson K. E., J. Urol., 130, 275-278 (1983).
39. Kirby R. S., Coppinger S. W. C., Corcoran M. O., Chapple C. R., Flannigan M., Milory E. J. G., Br. J. Urol., 60, 136-142 (1987).
40. Iskovitz H. D., Clin Ther., 16, 490-504 (1994).
41. Kyncl J. J., J. Clin. Pharmacol., 33, 878-883 (1993).
42. Wilde M. I., Filton A., Sorkin K. M., Drugs Aging, 3, 258-277 (1993).
43. Rochrborn C. G., Ocsterling J. E., Auerbach S., Urology, 47, 159-168 (1996).
44. Elhilai M. M., Ramsey E. W., Barkin J., Urology, 47, 335-342 (1996).
45. Babamato K. S., Hirokuwa W. T., Clin. Pharm., 11, 415-425 (1992).
46. Stokke H. P., J. Cardiovasc. Pharmacol., 33, 791-797 (1999).
47. Langton C. G., Packard R. S., Br. J. Clin. Pract., 48, 293-298 (1994).
48. Fawzy A., Braun K., Lewis G. P., Gaffney M., Ice K., Dias N., J. Urol., 154, 105-109 (1995).
49. Wilde M. I., McTavish D., Drugs, 52, 883-898 (1996).
50. Beduschi M. C., Beduschi R., Oesterling J. E., Urology, 51, 861-872 (1998).
51. Lepor H., J. Urol., 153, 274 (1995).
52. Yasukawa K., Swarz H., Ito Y., J. Int. Med. Res., 29, 236-251 (2001).
53. Raz S., Zholer M., Caine M., Br. J. Urol., 45, 663-667 (1973).
54. Caine M., J. Urol., 136, 1-6 (1986).
55. Caine M., Raz. S., Ziegler M., Br. J. Urol., 47, 193-202 (1975).
56. Chapple C. R., Aubury M. L., James S., J. Urol., 128, 836-839 (1982).
57. Furuya S., Kumamoto Y., Yokoyama E., Tsukamoto T., Izumi T., Abiko Y., J. Urol., 128, 836-839 (1982).